Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
McKesson
Moodys
Mallinckrodt
AstraZeneca

Last Updated: September 27, 2022

Details for Patent: 8,653,094


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,653,094 protect, and when does it expire?

Patent 8,653,094 protects XERMELO and is included in one NDA.

This patent has twenty-nine patent family members in twenty-five countries.

Summary for Patent: 8,653,094
Title:Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phen- yl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use
Abstract: Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phen- yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate and salts thereof are disclosed.
Inventor(s): Bednarz; Mark S. (Yardley, PA), De Paul; Susan (Zurich, CH), Kanamarlapudi; Ramanaiah C. (Bridgewater, NJ), Perlberg; Anett (Gunzgen, CH), Zhang; Haiming (San Mateo, CA)
Assignee: Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)
Application Number:13/486,103
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,653,094

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tersera XERMELO telotristat etiprate TABLET;ORAL 208794-001 Feb 28, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,653,094

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 068558 See Plans and Pricing
Australia 2008304439 See Plans and Pricing
Brazil PI0817270 See Plans and Pricing
Canada 2700835 See Plans and Pricing
Chile 2008002880 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Express Scripts
AstraZeneca
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.